Stocks and Investing
Stocks and Investing
Thu, May 22, 2014
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, May 21, 2014
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, May 20, 2014
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, May 19, 2014
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matt Miksic Upgraded (ABT) to Buy on, May 19th, 2014
Matt Miksic of Credit Suisse, Upgraded "Abbott Laboratories" (ABT) to Buy on, May 19th, 2014.
Matt has made no other calls on ABT in the last 4 months.
There is 1 other peer that has a rating on ABT. Out of the 1 peers that are also analyzing ABT, 0 agree with Matt's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matt
- Rick Wise of "Stifel" Maintained at Strong Buy with Increased Target to $42 on, Thursday, January 23rd, 2014
Contributing Sources